Deep Dive

Deep Dive/ Market Access/ Views & Analysis

ICSs: improving patient and market access at a local level

mike.hammerton@pharmaphorum.com Deep Dive, Deep Dive: Market Access, Dr Paul Tunnah, IQVIA, Jim McArdle, market access, Matthias Winker, Steven Ferguson, Uday Bose 0 Comment

Integrated Care Systems (ICSs) – 42 partnerships of health and care organisations who will plan and deliver more

ICSs: improving patient and market access at a local level

https://pharmaphorum.com/market-access-2/icss-improving-patient-and-market-access-at-a-local-level/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Time is motor neurons – the importance of newborn screening in SMA

mike.hammerton@pharmaphorum.com Deep Dive, Deep Dive: Market Access, market access, Mike Fraser, Novartis Gene Therapies, spinal muscular atrophy 0 Comment

Spinal muscular atrophy (SMA) is a devastating, genetic neuromuscular disease caused by a lack of a functional SMN1

Time is motor neurons – the importance of newborn screening in SMA

https://pharmaphorum.com/market-access-2/time-is-motor-neurons-the-importance-of-newborn-screening-in-sma/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Is it time to rethink electronic prescribing in the US?

mike.hammerton@pharmaphorum.com Bob Katter, Deep Dive, Deep Dive: Market Access, market access 0 Comment

It is a fact of life that most – if not all – patients will require some form

Is it time to rethink electronic prescribing in the US?

https://pharmaphorum.com/market-access-2/time-to-rethink-electronic-prescribing-us/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Combination pricing: access to the future of oncology treatment relies on collaboration

mike.hammerton@pharmaphorum.com Deep Dive, Deep Dive: Market Access, market access, Oncology, Sanofi 0 Comment

Combination therapies are fast becoming the cornerstone of cancer treatment: not just in the UK, but across the

Combination pricing: access to the future of oncology treatment relies on collaboration

https://pharmaphorum.com/market-access-2/combination-pricing-access-future-oncology-treatment-relies-collaboration/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Closing the digital expectation gap in pharma

mike.hammerton@pharmaphorum.com Deep Dive, Deep Dive: Market Access, Jan Deman, market access, Takeda 0 Comment

Jan Deman is Takeda’s head of digital customer experience for Europe and Canada. But he’d prefer not to

Closing the digital expectation gap in pharma

https://pharmaphorum.com/market-access-2/closing-the-digital-expectation-gap-in-pharma/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

How do we make patient centricity a reality?

mike.hammerton@pharmaphorum.com Deep Dive, Deep Dive: Market Access, Evidation, market access, Mikki Nasch 0 Comment

For years, the subject of fostering direct connections with patients has been highlighted by notable figures across the

How do we make patient centricity a reality?

https://pharmaphorum.com/market-access-2/how-do-we-make-patient-centricity-a-reality/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Leveraging KOL insights to succeed in a data-driven world

mike.hammerton@pharmaphorum.com Christina L Hoffman, Deep Dive, Deep Dive: Market Access, market access, Medscape Medical Affairs 0 Comment

For years, key opinion leaders (KOLs) have held a position of authority and respect amongst those working across

Leveraging KOL insights to succeed in a data-driven world

https://pharmaphorum.com/market-access-2/leveraging-kol-insights-to-succeed-in-a-data-driven-world/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Rethinking value: why diverse viewpoints matter

mike.hammerton@pharmaphorum.com Axon, Deep Dive, Deep Dive: Market Access, market access, Shanida Nataraja 0 Comment

Value is a tricky concept to capture accurately. Given the diverse and complex world that we live in,

Rethinking value: why diverse viewpoints matter

https://pharmaphorum.com/market-access-2/rethinking-value-why-diverse-viewpoints-matter/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Deep Dive: Market Access

mike.hammerton@pharmaphorum.com Axon, Deep Dive, market access, Medscape, Novartis, Takeda 0 Comment

For life science companies around the world, enabling faster access to innovative drugs and therapies is a complicated

Deep Dive: Market Access

https://pharmaphorum.com/market-access-2/deep-dive-market-access-2022/

1 2 3 4 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

Deep Dive

Login